Display options
Share it on

Med Oncol Tumor Pharmacother. 1990;7(4):219-22. doi: 10.1007/BF02987098.

Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).

Medical oncology and tumor pharmacotherapy

P Weynants, Y Humblet, A Bosly, D Schallier, P Duprez, F Majois, M Beauduin, J Prignot, M Symann

Affiliations

  1. UCL Clinical Oncology Group, Cliniques Universitaires St. Luc, Brussels, Belgium.

PMID: 2178205 DOI: 10.1007/BF02987098

Abstract

Carboplatin, a second generation platinum complex, is less nephrotoxic and emetogenic than its parent compound. We have tested the objective response to and the toxicity of the combination carboplatin 330 mg m-2 on day 1 with etoposide 120 mg m-2 on days 1, 3 and 5, administered every 3 weeks in histologically proven inoperable non-small-cell lung cancer (NSCLC) patients with a good performance status. Thirty-one patients entered the study; 29 were evaluable for response, 24 after 3 courses and 5 after 2 courses of chemotherapy. An overall response rate of 21% was found including zero complete response and 6 partial responses. In addition, 3 minor responses (10%), 12 stable diseases (38%), and 9 progressive diseases (39%) were observed. The median survival was 48 weeks, including 68 weeks for non-metastatic (M0) patients and 27 weeks for metastatic (M+) patients. This regimen was well tolerated. Gastrointestinal toxicity never exceeded WHO grade II and renal function remained in the normal range for all cases. Haematological toxicity was low in the majority of the cases; nevertheless it proved to be the dose limiting toxicity as illustrated by two grade III anemia, one grade III leucopenia, one grade III and one grade IV thrombocytopenia. Carboplatin-etoposide combination is not more active, but clearly much less toxic than cisplatin-etoposide in NSCLC.

Similar articles

References

  1. Semin Oncol. 1985 Dec;12(4 Suppl 6):38-48 - PubMed
  2. Ann Intern Med. 1984 May;100(5):704-13 - PubMed
  3. J Clin Oncol. 1987 Feb;5(2):185-9 - PubMed
  4. Cancer Treat Rep. 1982 Jan;66(1):135-46 - PubMed
  5. J Clin Oncol. 1986 Jul;4(7):1037-43 - PubMed
  6. Semin Oncol. 1986 Sep;13(3 Suppl 3):104-14 - PubMed
  7. J Clin Oncol. 1986 Jan;4(1):14-22 - PubMed
  8. J Clin Oncol. 1988 Apr;6(4):633-41 - PubMed
  9. Cancer Treat Rep. 1987 Nov;71(11):1049-52 - PubMed
  10. Ann Intern Med. 1981 Oct;95(4):414-20 - PubMed
  11. J Clin Oncol. 1986 Nov;4(11):1704-15 - PubMed
  12. Cancer. 1981 Jan 1;47(1):207-14 - PubMed
  13. Cancer Treat Rep. 1986 Mar;70(3):421-2 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources